Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects.

doi:10.1007/s00228-004-0767-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects.

European journal of clinical pharmacology - 1 Jun 2004

Eap Chin B, Buclin Thierry, Hustert Elisabeth, Bleiber Gabriela, Golay Kerry Powell, Aubert Anne-Catherine, Baumann Pierre, Telenti Amalio, Kerb Reinhold

Abstract excerpt

OBJECTIVE: We investigated whether differences in pharmacokinetics of midazolam, a CYP3A probe, could be demonstrated between subjects with different CYP3A4 and CYP3A5 genotypes. METHODS: Plasma concentrations of midazolam, and of total (conjugated + unconjugated) 1'OH-midazolam, and 4'OH-midazolam were measured after the oral administration of 7.5 mg or of 75 micro g of midazolam in 21 healthy subjects. RESULTS:...

Topics

Area Under Curve
Cytochrome P-450 CYP3A
Cytochrome P-450 Enzyme System
Female
Genotype
Humans
Male
Midazolam

Source

Open in PubMed

Identifiers

PMID: 15114431
DOI: 10.1007/s00228-004-0767-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics